Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

PHASE3CompletedINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

November 30, 2010

Conditions
Epilepsies, Partial
Interventions
DRUG

Placebo

Non-active tablet identical to study drug tablets

DRUG

2400mg SPN-804

tablets containing 600mg OXC XR, identical to non-active tablets

DRUG

1200mg SPN-804

two active tablets and two non-active tablets, all identical

Trial Locations (71)

Unknown

Huntsville

Northport

Phoenix

Tucson

Little Rock

Riverside

West Los Angeles

Aurora

Jacksonville

Miami

Sarasota

Atlanta

Springfield

Lexington

Bethesda

Missoula

Camden

New York

Oklahoma City

Philadelphia

Nashville

Baytown

Temple

Blagoevgrad

Pleven

Plovdiv

Rousse

Sofia

Varna

Edmonton

Greenfield Park

Dubrovnik

Rijeka

Zadar

Zagreb

Aguascalientes

Chihuahua City

Ciudad Juárez

Durango

Guadalajara

Zapopan

Mexico City

Monterrey

Puebla City

San Luis Potosí City

Toluca

Giżycko

Gmina Końskie

Katowice

Krakow

Lodz

Lublin

Warsaw

Wilkowice

Zabrze

Bucharest

Campulung Muscel

Cluj-Napoca

Craiova

Saint Petersburg

Kazan'

Kirov

Kursk

Moscow

Nizhny Novgorod

Novosibirsk

Pyatigorsk

Saint Petersburg

Samara

Smolensk

Yaroslavl

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

Supernus Pharmaceuticals, Inc.

INDUSTRY